Global NGS-based RNA-seq Market Strategic Research Report

Scope of the Report

The global NGS-based RNA-seq market size is predicted to grow from US$ 3,931 million in 2025 to US$ 7,957 million in 2032; it is expected to grow at a CAGR of 10.6% from 2026 to 2032.

The gross profit margin of major companies in the industry was approximately 45%–70%.

NGS-based RNA Sequencing is a molecular analysis technology that uses next-generation sequencing to identify, quantify, and characterize RNA molecules, enabling analysis of gene expression, transcript structures, and biological variation. Products and services mainly include RNA sequencing workflows, sequencing reagents, library preparation solutions, and sequencing services for scientific research, drug development, clinical research, biotechnology, agriculture, and precision medicine.

The industrial chain of NGS-based RNA Sequencing includes upstream sequencing reagents, library preparation materials, sequencing instruments, laboratory consumables, and bioinformatics technologies; midstream covers sample processing, library construction, sequencing, quality control, and data analysis; downstream applications mainly include academic research, pharmaceutical development, clinical research, biotechnology, agriculture, and precision medicine.

NGS-based RNA sequencing is a high-throughput molecular analysis approach that uses next-generation sequencing technologies to characterize RNA molecules, enabling comprehensive analysis of gene expression, transcript structures, alternative splicing, gene fusions, and other transcriptomic features. It is widely applied in basic biological research, oncology, drug discovery and development, biomarker research, precision medicine, and other life science applications. Compared with conventional targeted expression analysis methods, NGS-based RNA sequencing provides broader transcriptome coverage and greater capability to identify previously unknown transcripts and molecular changes. Market development is being driven by continued advances in sequencing platforms, library preparation, bioinformatics, and computational analysis, which are improving throughput, sensitivity, reproducibility, and workflow efficiency. Growing investment in genomics and transcriptomics research, expanding cancer and rare disease studies, increasing pharmaceutical research activity, and rising demand for precision medicine are supporting broader adoption. Important opportunities are emerging from single-cell and spatial transcriptomics, liquid biopsy research, clinical biomarker development, immune profiling, and integration of RNA sequencing with genomics, proteomics, and other multi-omics approaches. Increasing automation of sample preparation and data analysis may further improve accessibility across research and clinical laboratories. However, market development remains constrained by sequencing and computational costs, complex sample preparation, large data processing requirements, challenges in standardizing analytical workflows, and the need for specialized bioinformatics expertise. Clinical adoption also requires robust validation, reproducibility, and compliance with regulatory requirements. Continued improvements in sequencing efficiency, analytical software, automation, and cost effectiveness are expected to expand the role of NGS-based RNA sequencing in biomedical research and selected clinical applications.

This report presents a comprehensive overview of the global NGS-based RNA-seq market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Whole Transcriptome Sequencing
• Targeted RNA Sequencing
• Small RNA Sequencing

Segment by Library Preparation Method

• Poly(A) Enrichment-based Sequencing
• rRNA Depletion-based Sequencing
• Capture and Amplicon-based Sequencing

Segment by Sequencing Depth per Sample

• Low-depth（≤20 Million Reads）
• Medium-depth（＞20–100 Million Reads）
• High-depth（＞100 Million Reads）

Segment by players, this report covers

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Takara Bio Inc.
• Azenta, Inc.
• Eurofins Scientific SE
• BGI Americas Corporation
• Macrogen, Inc.
• Ebiogen Inc.
• Theragen Bio Co., Ltd.
• Psomagen, Inc.
• GeneMotions Co., Ltd.
• BGI Genomics Co., Ltd.
• MGI Tech Co., Ltd.
• Novogene Co., Ltd.
• Annoroad Gene Technology Co., Ltd.
• Shanghai OE Biotech Co., Ltd.
• LC-Bio Technology Co., Ltd.
• Guangzhou Gene Denovo Biotechnology Co., Ltd.
• Biomarker Technologies Corporation
• Berry Genomics Co., Ltd.
• CapitalBio Technology Co., Ltd.

Segment by Application

• Gene Expression Profiling
• Biomarker and Disease Research
• Fusion, Splicing and Transcript Variant Analysis
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global NGS-based RNA-seq market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Gene Expression Profiling, Biomarker and Disease Research, Fusion, Splicing and Transcript Variant Analysis evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact